Understanding early uptake of insulin biosimilars in NHs, where diabetes and insulin use are prevalent, may help to anticipate the trajectory of use in other clinical settings in the US while also providing due attention to a vulnerable population. The gene discussed is INS; the disease is diabetes mellitus.